Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melanoma-TBK1-inhibitor enhanced Immunotherapy with Checkpoint Inhibitors
2026-526821-16-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in cutaneous melanoma (CM) and melanoma comparing Omjjara + Keytruda with Omjjara + Opdivo (2 arms). Primary endpoints: Phase Ib safety and tolerability, Phase Ib dose-limiting toxicities and recommended Phase II dose and 2 more. Planned start Jul 2026; status: authorised.
02
Drugs
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2026-526821-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526821-16-00.